Synaptogenix Changes Fiscal Year End

TL;DR

Synaptogenix just changed its fiscal year end to Dec 31st, effective Sept 3rd.

AI Summary

Synaptogenix, Inc. filed an 8-K on September 9, 2024, reporting a change in its fiscal year end to December 31st. This change was effective as of September 3, 2024. The company, formerly known as Neurotrope Bioscience, Inc., is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.

Why It Matters

A change in fiscal year end can impact reporting schedules and financial analysis timelines for investors and analysts.

Risk Assessment

Risk Level: low — This filing is administrative and does not involve significant financial or operational changes.

Key Numbers

• 1231 — New Fiscal Year End (The company will now close its books on December 31st annually.)

Key Players & Entities

• Synaptogenix, Inc. (company) — Registrant
• September 3, 2024 (date) — Effective date of fiscal year change
• December 31 (date) — New fiscal year end
• Neurotrope Bioscience, Inc. (company) — Former company name
• Delaware (jurisdiction) — State of incorporation

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share SNPX The Nasdaq

Filing Documents

• tm2423592d2_8k.htm (8-K) — 25KB
• tm2423592d2_ex3-1.htm (EX-3.1) — 10KB
• 0001104659-24-098197.txt ( ) — 211KB
• snpx-20240903.xsd (EX-101.SCH) — 3KB
• snpx-20240903_lab.xml (EX-101.LAB) — 33KB
• snpx-20240903_pre.xml (EX-101.PRE) — 22KB
• tm2423592d2_8k_htm.xml (XML) — 4KB

03 Amendments to Articles of Incorporation

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. As previously disclosed, on November 21, 2022, Synaptogenix, Inc. (the "Company") filed a Certificate of Designations of Series B Convertible Preferred Stock of Synaptogenix, Inc. (the "Certificate of Designations") with the Secretary of State of the State of Delaware (the "Delaware Secretary of State"), thereby creating a new series of preferred stock of the Company designated as "Series B Convertible Preferred Stock" (the "Preferred Shares"). Also as previously disclosed, the Company filed Certificates of Amendment to the Certificate of Designations with the Delaware Secretary of State on each of March 17, 2023, May 12, 2023 and September 22, 2023. On September 3, 2024, the Company filed a Certificate of Amendment to the Certificate of Designations (the "Amendment") with the Delaware Secretary of State. Pursuant to the Amendment, the maturity date of the Preferred Shares was extended from August 31, 2024 to September 9, 2024, subject to further extension pursuant to the terms of the Certificate of Designations. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. Exhibit Description 3.1 Certificate of Amendment to Certificate of Designations of Series B Convertible Preferred Stock of Synaptogenix, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SYNAPTOGENIX, INC. Date: September 9, 2024 By: /s/ Robert Weinstein Name: Robert Weinstein Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR